Result: Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy
Involved:
Published:
Freiburg : Universität, 2022
Scope:
1 Online-Ressource
Format:
Language:
English
Notes:
Cancers. - 14, 3 (2022) , 540, ISSN: 2072-6694
DOI:
10.3390/cancers14030540